Association Between Human Blood Metabolome and the Risk of Psychiatric Disorders

• Published in: Schizophrenia bulletin Vol. 49; no. 2; pp. 428 - 443
• Main Authors: Jia, Yiming, Hui, Li, Sun, Lulu, Guo, Daoxia, Shi, Mengyao, Zhang, Kaixin, Yang, Pinni, Wang, Yu, Liu, Fanghua, Shen, Ouxi, Zhu, Zhengbao
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 15.03.2023
• Subjects: 3-Hydroxybutyric Acid; Attention Deficit Disorder with Hyperactivity; Depressive Disorder, Major; Genome-Wide Association Study; Humans; Mendelian Randomization Analysis; Mental disorders; Metabolites; Regular; antipsychotics; Mendelian randomization; metabolites; biomarkers; psychiatric disorders
• ISSN: 0586-7614; 1745-1701; 1745-1701
• DOI: 10.1093/schbul/sbac130

Abstract Background and Hypothesis To identify promising drug targets for psychiatric disorders, we applied Mendelian randomization (MR) design to systematically screen blood metabolome for potential mediators of psychiatric disorders and further predict target-mediated side effects. Study Design We selected 92 unique blood metabolites from 3 metabolome genome-wide association studies (GWASs) with totally 147 827 participants. Summary statistics for bipolar disorder (BIP), attention deficit hyperactivity disorder (ADHD), obsessive-compulsive disorder (OCD), major depressive disorder (MDD), schizophrenia (SCZ), panic disorder (PD), autistic spectrum disorder (ASD), and anorexia nervosa (AN) originated from the Psychiatric Genomics Consortium, involving 1 143 340 participants. Mendelian randomization (MR) analyses were conducted to estimate associations of blood metabolites with psychiatric disorders. Phenome-wide MR analysis was further performed to predict side effects mediated by metabolite-targeted interventions. Results Eight metabolites were identified associated with psychiatric disorders, including five established mediators: N-acetylornithine (BIP: OR, 0.72 [95% CI, 0.66–0.79]; SCZ: OR, 0.74 [0.64–0.84]), glycine (BIP: OR, 0.62 [0.50–0.77]), docosahexaenoic acid (MDD: OR, 0.96 [0.94–0.97]), 3-Hydroxybutyrate (MDD: OR, 1.14 [1.08–1.21]), butyrylcarnitine (SCZ: OR, 1.22 [1.12–1.32]); and three novel mediators: 1-arachidonoylglycerophosphocholine (1-arachidonoyl-GPC)(BIP: OR, 0.31 [0.23–0.41]), glycoproteins (BIP: OR, 0.94 [0.92–0.97]), sphingomyelins (AN: OR, 1.12 [1.06–1.19]). Phenome-wide MR analysis showed that all identified metabolites except for N-acetylornithine and 3-Hydroxybutyrate had additional effects on nonpsychiatric diseases, while glycine, 3-Hydroxybutyrate, N-acetylornithine, and butyrylcarnitine had no adverse side effects. Conclusions This MR study identified five established and three novel mediators for psychiatric disorders. N-acetylornithine, glycine, 3-Hydroxybutyrate, and butyrylcarnitine might be promising targets against psychiatric disorders with no predicted adverse side effects.